Sign In
Buy TNXP
$12.20
+0.190 (+1.58%)
At Close: Jun 22, 2026
TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Unique sublingual formulation designed for bedtime dosing bypasses first-pass metabo
Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026
07:00am, Tuesday, 06'th Jan 2026
BERKELEY HEIGHTS, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully integrated, commercial biotechnology company, announced tod
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering
07:57am, Monday, 29'th Dec 2025
CHATHAM, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial stage biotechnology company, today
Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field study
Tonix Pharmaceuticals (NASDAQ:TNXP) & Citius Pharmaceuticals (NASDAQ:CTXR) Head to Head Contrast
02:00am, Friday, 19'th Dec 2025
Citius Pharmaceuticals (NASDAQ: CTXR - Get Free Report) and Tonix Pharmaceuticals (NASDAQ: TNXP - Get Free Report) are both small-cap medical companies, but which is the superior business? We will con
Non-opioid analgesic shows efficacy in several animal pain models, including diabetic and chemotherapy-induced neuropathic pain
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel
07:00am, Tuesday, 09'th Dec 2025
Ms. Ishak brings more than 25 years of corporate legal and strategic leadership experience in the life sciences industry Ms. Ishak brings more than 25 years of corporate legal and strategic leadership
Tonix: Maintaining Buy Rating With Potential Tonmya Expansion Indications
03:35pm, Monday, 24'th Nov 2025
Tonix Pharmaceuticals Holding Corp. received FDA approval and launched Tonmya, the first new fibromyalgia drug in over 15 years. TNXP is expanding Tonmya into acute stress disorder [ASD] and major dep
Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder
07:00am, Monday, 24'th Nov 2025
Tonix plans to initiate potential pivotal Phase 2 HORIZON study of TNX-102 SL in adults with major depressive disorder in mid-2026
TONMYA is now available by prescription and available for pharmacy ordering nationwide TONMYA is the first FDA-approved treatment for fibromyalgia in more than 15 years TONMYA is a unique, non-opioid,
Tonix Q3 2025 Earnings Recap And Tonmya Launch Outlook
09:41am, Friday, 14'th Nov 2025
Tonix Pharmaceuticals is preparing for the commercial launch of Tonmya, a new FDA-approved fibromyalgia therapy, in November 2025. 3Q25 results showed revenue growth and a strong cash position, but hi
Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights
04:15pm, Monday, 10'th Nov 2025
Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia set to launch in November Tonmya is the first new FDA-approved medicine for fibromyalgia in more than 15 years Cash
Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference
07:00am, Thursday, 06'th Nov 2025
CHATHAM, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial biotechnology company, today annou
Head-To-Head Review: Tonix Pharmaceuticals (NASDAQ:TNXP) versus ProKidney (NASDAQ:PROK)
02:46am, Wednesday, 05'th Nov 2025
Tonix Pharmaceuticals (NASDAQ: TNXP - Get Free Report) and ProKidney (NASDAQ: PROK - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two bu
Planning to initiate an open-label Phase 2 study of TNX-1500 under an investigator-initiated IND to evaluate safety and activity in the first half of 2026
